publication venue for
- Utility Measurement in Healthcare 2006
- Information Barriers to the Implementation of Economic Evaluations in Japan 2002
- The Development and Use of Quality-of-Life Measures to Evaluate Health Outcomes in Japan 2002
- Why Has the Use of Health Economic Evaluation in Japan Lagged Behind that in Other Developed Countries? 2002
- Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis. 42:41-68. 2024
- Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis. 42:41-68. 2024
- Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies. 41:1453-1467. 2023
- Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study. 41:439-455. 2023
- China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population. 40:957-969. 2022
- The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada. 40:917-928. 2022
- Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT). 39:1075-1084. 2021
- Sustainability of Publicly Funded Health Care Systems: What Does Behavioural Economics Offer?. 38:1289-1295. 2020
- Measuring Public Preferences for Health Outcomes and Expenditures in a Context of Healthcare Resource Re-Allocation. 37:407-417. 2019
- Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation. 36:883-888. 2018
- Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies. 34:1087-1100. 2016
- BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles. 34:1051-1065. 2016
- Using Linear Equating to Map PROMIS® Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3. 34:1015-1022. 2016
- Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters. 33:1083-1090. 2015
- A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). 33:867-877. 2015
- The Silence in Hoch et al.’s Commentary about the Rationale for and Objective(s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers’ Dollars. 33:883-886. 2015
- Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?. 33:235-241. 2015
- Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes. 32:995-1004. 2014
- A Review of the Psychometric Properties of Generic Utility Measures in Multiple Sclerosis. 32:759-773. 2014
- Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis. 31:501-508. 2013
- Optimal Global Value of Information Trials: Better Aligning Manufacturer and Decision Maker Interests and Enabling Feasible Risk Sharing. 31:393-401. 2013
- The General Publicʼs Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimerʼs Disease Medication. 30:1085-1095. 2012
- A Parent-Child Dyad Approach to the Assessment of Health Status and Health-Related Quality of Life in Children with Asthma. 30:697-712. 2012
- Value of Information and Pricing New Healthcare Interventions. 30:447-459. 2012
- Common Drug Review Recommendations. 30:229-246. 2012
- Sample Size Determination for Cost-Effectiveness Trials. 29:933-949. 2011
- Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies. 29:563-577. 2011
- Advances in Cancer Therapeutics and Patient Access to New Drugs. 29:213-224. 2011
- Consistently Estimating Absolute Risk Difference when Translating Evidence to Jurisdictions of Interest. 29:87-96. 2011
- The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions. 28:1079-1096. 2010
- The Value of Value of Information. 28:699-709. 2010
- Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy. 28:585-595. 2010
- Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma. 28:597-608. 2010
- A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment. 28:255-277. 2010
- Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy A Pragmatic Trial. 28:585-595. 2010
- Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma A Pragmatic Trial. 28:597-608. 2010
- Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada. 26:477-495. 2008
- Being Led Down the Wrong Garden PATH: the Importance of Knowledge and Facts for the Crossroads. 25:528-532. 2007
- Building Bridges Between Academic Research and Policy Formulation: When Costing Less Means Costing More. 25:523-528. 2007
- Estimation, Power and Sample Size Calculations for Stochastic Cost and Effectiveness Analysis. 25:455-466. 2007
- The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD). 25:385-396. 2007
- ???Lost in Translation???. 24:1101-1119. 2006
- Building Bridges Between Academic Research and Policy Formulation. 24:1143-1156. 2006
- Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients. 24:593-607. 2006
- Economic Evaluation of Rivastigmine in Patients with Parkinson??s Disease Dementia. 24:93-106. 2006
- Information Created to Evade Reality (ICER). 24:1121-1131. 2006
- The authors’ reply. 23:853-853. 2005
- Incorporation of uncertainty in health economic modelling studies. 23:529-536. 2005
- Antiviral Agents for Influenza. 23:1083-1106. 2005
- The NICE Reference Case Requirement. 22:271-273. 2004
- NICE Methodological Guidelines and Decision Making in the National Health Service in England and Wales. 21:149-157. 2003
- Putting Your Money Where Your Mouth Is. 20:245-255. 2002
- The Economic Costs of Early Stage Prostate Cancer. 20:869-878. 2002
- Cost Effectiveness in Canada of a Multidrug Prepackaged Regimen (Hp-PAC??)* for Helicobacter pylori Eradication. 19:831-843. 2001
- Glycoprotein IIb/IIIa Receptor Therapy in Percutaneous Coronary Intervention and Non???ST-Segment Elevation Acute Coronary Syndromes. 19:41-55. 2001
- Highly Active Antiretroviral Therapy. 19:709-713. 2001
- Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis. 19:1039-1049. 2001
- Using Humanistic Health Outcomes Data in Asthma. 19:13-19. 2001
- The Economic Value of a New Insulin Preparation, Humalog?? Mix 25???. 18:275-287. 2000
- Economic Evaluation of Ciprofloxacin Compared with Usual Antibacterial Care for the Treatment of Acute Exacerbations of Chronic Bronchitis in Patients Followed for 1 Year. 16:499-520. 1999
- Economic Evaluation of Long Term Management Strategies for Erosive Oesophagitis. 16:679-697. 1999
- Hospital Selection for Unit Cost Estimates in Multicentre Economic Evaluations. 15:561-572. 1999
- Incremental Cost-Effectiveness Analysis of Intravenous Ganciclovir Versus Oral Ganciclovir in the Maintenance Treatment of Newly Diagnosed Cytomegalovirus Retinitis in Patients with AIDS. 16:71-84. 1999
- The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. 15:459-468. 1999
- Willingness to Pay and the Valuation of Programmes for the Prevention and Control of Influenza. 16:55-61. 1999
- Workshop 1: Appraising the Methods for Economic Evaluation. 16:91-93. 1999
- Cost Effectiveness of Multi-Therapy Treatment Strategies in the Prevention of Vertebral Fractures in Postmenopausal Women with Osteoporosis. 14:559-573. 1998
- Willingness To Pay. 14:465-470. 1998
- Reassessing Quality-of-Life Instruments in the Evaluation of New Drugs. 12:621-626. 1997
- Health Status Assessment of the Elderly. 12:533-546. 1997
- Guidelines for Pharmacoeconomic Studies. 11:159-168. 1997
- Canadian Guidelines for Economic Evaluation of Pharmaceuticals. 9:535-559. 1996
- Switching the Histamine H2 Receptor Antagonist Famotidine to Nonprescription Status in Canada. 9:61-75. 1996
- Modelling the Cost Effectiveness of Antidepressant Treatment in Primary Care. 8:524-540. 1995
- OUALITY-OF-LIFE CONSIDERATIONS IN THE TREATMENT OF ASTHMA. 8:123-138. 1995
- Quality-of-Life Considerations in the Treatment of Asthma. 8:123-138. 1995
- Assessing the Economic Value of a New Antidepressant. 8:34-45. 1995
- Quality of Life in Cystic Fibrosis. 8:23-33. 1995
- Multi-Attribute Health Status Classification Systems. 7:490-502. 1995
- Multi-Attribute Preference Functions. 7:503-520. 1995
- Clinical Decision Making vs Programme Evaluation Perspectives. 4:228-231. 1993
- Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs).. 1:338-345. 1992
- Key Quality of Life Terms Used in the Evaluation of New Drugs. 1:94-94. 1992
- Quality of Life Instruments in the Evaluation of New Drugs. 1:84-94. 1992